News & Updates

In the CONFIDENT trial, convalescent plasma (CCP) conferred a mortality benefit for patients with COVID-19-induced acute respiratory distress syndrome (ARDS) who were on invasive mechanical ventilation (IMV).

Individuals with intracranial atherosclerosis disease (ICAD) have a heightened risk of cognitive impairment and dementia, according to the results of a systematic review and meta-analysis.

Empowering mums to self-monitor their blood pressure (BP) with a physician-guided titration of antihypertensive medications helps lower postpartum BP level after a pregnancy complicated by hypertension, as shown in the POP-HT trial.

In the phase III BOREAS trial, the monoclonal antibody dupilumab conferred multiple benefits for individuals with chronic obstructive pulmonary disease (COPD) and type 2 (T2) inflammation.

In the treatment of older patients with metastatic castration-resistant prostate cancer (mCRPC) who are considered unsuitable candidates for standard cabazitaxel (CBZ) regimens, treatment with CBZ at 16 mg/m2 (biweekly CBZ16) plus prophylactic granulocyte colony–stimulating factor (G-CSF) at each cycle helps reduce the risk of higher grade neutropenia and/or neutropenic complications while yielding similar clinical outcomes, according to the results of the phase III CABASTY trial.